Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for cardiovascular prevention in hemodialysis patients
NCT01198379Phase 4Withdrawn
- Sponsor
- Buddhist Tzu Chi Medical Foundation
- Start
- Feb 2010
- Primary completion
- Jan 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aspirin in cardiovascular disease (CVD) and Vascular access thrombosis (VAT) (2 arms), sponsored by Buddhist Tzu Chi Medical Foundation. Primary endpoint: Prevalence of aspirin resistance at 3 years. Planned start Feb 2010; status: withdrawn.
02
Drugs
aspirin
03
Conditions
cardiovascular disease (CVD)Vascular access thrombosis (VAT)
Beyond the preview
Go deeper on NCT01198379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198379.